Aviado · Research
Longevity Daily
Friday, November 20, 2026
Listen
Today's Brief
The most urgent story today is a twice-yearly Alzheimer's injection that cut cognitive decline by 54% in early-stage patients — results the scientific community is calling "thrilling." A separate trial of a daily cortisol-blocking pill is showing 30% slower disease progression, suggesting multiple pathways to slowing dementia are now in play. On the supplement front, a Cochrane review deals a blow to turmeric, while Aviado Research unpacks the real L-carnitine trade-off between mitochondrial fuel and cardiovascular risk. Meanwhile, rapamycin makes another leap forward with the first primate lifespan trial and a new Mount Sinai combination study.
10 stories1 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Twice-Yearly Alzheimer's Injection Cuts Cognitive Decline by 54% in Major Trial
A new drug called diranersen, given just twice a year, reduced the rate of cognitive decline by 54% in early-stage Alzheimer's patients — results leading researchers are calling "thrilling" and "very encouraging." The study marks one of the most dramatic readouts in Alzheimer's history, targeting a molecular pathway distinct from the amyloid antibodies currently approved, with a dosing schedule that could dramatically improve real-world adherence. If confirmed in larger trials, this twice-yearly injection could become the most accessible disease-modifying treatment yet, potentially preserving memory and independence for millions of patients worldwide.
Read more →Daily Cortisol-Blocking Pill Slows Alzheimer's Progression by 30%, Trial Shows
Xanamem, a once-daily pill that lowers cortisol levels in the brain, slowed Alzheimer's disease progression by up to 30% in early trial results — lending new support to the idea that chronic stress hormones are an underappreciated driver of neurodegeneration. The finding opens a drug target distinct from amyloid and tau, potentially complementing rather than competing with existing disease-modifying therapies. These are early-phase results and larger confirmatory trials will be needed before drawing firm conclusions.
Read more →The Gut-Derived Compound in Pomegranates That May Protect Against Alzheimer's
A new review highlights urolithins — molecules produced by gut bacteria when you eat pomegranates, berries, and walnuts — as promising neuroprotective agents with potential to guard against Alzheimer's disease. The research identifies multiple mechanisms including neuroinflammation reduction and mitochondrial support in brain cells, though only an estimated 40% of people produce urolithins efficiently from diet alone. Urolithin A supplements are emerging as an accessible way to capture these benefits regardless of your individual gut microbiome composition.
Read more →Supplements & Compounds
L-Carnitine for Fat Burning: Weighing the TMAO Trade-Off
L-carnitine consistently lowers liver enzymes (ALT/AST by 8–12 points) and supports mitochondrial fat oxidation — but gut bacteria in many people convert it to TMAO, a compound linked to cardiovascular risk in observational studies. The critical nuance from Aviado Research: vegetarians typically produce far less TMAO than meat-eaters, meaning your dietary background largely predicts your risk profile. For most people, 1–3g daily delivers measurable biochemical benefits, but monitoring liver enzymes and starting at 1g is a sensible default.
Read the full Aviado analysis →Cochrane Review: Turmeric Supplements No Better Than Placebo for Arthritis Pain
A systematic review by Cochrane — the gold standard for evidence synthesis — found turmeric and curcumin supplements were no more effective than placebo or standard anti-inflammatory drugs for relieving osteoarthritis pain, across trials lasting four weeks to three months. The findings are a significant blow to one of the supplement industry's most popular anti-inflammatory products, though researchers note that most trials used standard curcumin formulations with notoriously poor bioavailability. If you're taking turmeric for joint pain, this review is a clear reason to reassess — or investigate a high-bioavailability formulation where the evidence remains less conclusive.
Read more →Creatine for Healthy Aging: What the Science Actually Says
Medical News Today's deep-dive finds the evidence meaningfully supports creatine for healthy aging — specifically for muscle mass preservation, cognitive function, and energy metabolism in older adults. Beyond the gym, creatine's ability to replenish phosphocreatine stores in both muscle and brain tissue gives it a credible dual-target profile that few other supplements can match. The standard dose of 3–5g daily is well-studied, inexpensive, and carries one of the strongest safety records of any compound in routine supplemental use.
Read more →Research & Papers
First Long-Term Rapamycin Trial in Primates Achieves 10–15% Lifespan Extension
Dr. Adam Salmon at UT Health San Antonio administered daily oral rapamycin to common marmosets starting in middle age, achieving 10–15% median lifespan extension in the first long-term rapamycin trial in non-human primates. Marmosets — with an average lifespan of 8–10 years — are a meaningfully closer evolutionary proxy to humans than mice, making these findings more translatable than the rodent data the longevity community has relied on for years. The results also included striking data on brain cell rejuvenation, adding a cognitive dimension to rapamycin's expanding potential profile.
Read more →Mount Sinai Launches Human Trial Combining Rapamycin, Spermidine, and Exercise
Researchers at Mount Sinai Hospital in New York are launching a clinical trial stacking three longevity interventions: structured exercise, spermidine supplementation, and rapamycin — combining two autophagy-activating compounds with physical training in a formal human study. This combinatorial approach is rare in longevity medicine, where most trials test single agents, and the mechanistic rationale is compelling: rapamycin and spermidine activate autophagy through distinct pathways that may produce additive or synergistic effects. If you've been following either compound in the literature, this is the trial to watch.
Read more →Lifestyle & Nutrition
Exercise Beats Diet for Longevity — And It's Not Even Close, New Analysis Finds
A large analysis found that in every comparison tested, physical activity and cardiorespiratory fitness showed a substantially stronger relationship to longevity outcomes than diet — a finding that held across different populations and study designs. The lead researcher stated plainly: "In every instance, it was physical activity or cardiorespiratory fitness that had a much stronger relationship to your longevity prospects." If you're deciding where to focus your health optimization effort, the data makes a clear case: the gym consistently outperforms the kitchen.
Read more →Industry & Policy
Physician-Led Longevity Platform Hone Health Raises $228 Million to Scale Personalized Care
Hone Health, which offers physician-supervised hormone optimization and personalized longevity protocols, has secured $228 million in financing — the latest signal that institutional capital is flowing into digital longevity medicine at scale. The funding will support new clinical programs and AI-driven care personalization tools that convert patient biomarker data into individualized plans, with backers including Gwyneth Paltrow's Kinship Ventures. The raise positions Hone at the intersection of two of healthcare's fastest-growing markets: telehealth and longevity medicine.
Read more →